- Home
- ISPC vs ZVSA Comparison
ISPC vs ZVSA Comparison
Compare ISPC & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- ZVSA
- Stock Information
- Founded
- ISPC 2009
- ZVSA 2014
- Country
- ISPC United States
- ZVSA United States
- Employees
- ISPC N/A
- ZVSA N/A
- Industry
- ISPC Precision Instruments
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- ZVSA Health Care
- Exchange
- ISPC Nasdaq
- ZVSA Nasdaq
- Market Cap
- ISPC 3.1M
- ZVSA 3.0M
- IPO Year
- ISPC 2021
- ZVSA N/A
- Fundamental
- Price
- ISPC $0.94
- ZVSA $0.69
- Analyst Decision
- ISPC
- ZVSA
- Analyst Count
- ISPC 0
- ZVSA 0
- Target Price
- ISPC N/A
- ZVSA N/A
- AVG Volume (30 Days)
- ISPC 51.4K
- ZVSA 1.5M
- Earning Date
- ISPC 08-05-2025
- ZVSA 08-08-2025
- Dividend Yield
- ISPC N/A
- ZVSA N/A
- EPS Growth
- ISPC N/A
- ZVSA N/A
- EPS
- ISPC N/A
- ZVSA N/A
- Revenue
- ISPC $8,058,631.00
- ZVSA N/A
- Revenue This Year
- ISPC $35.93
- ZVSA N/A
- Revenue Next Year
- ISPC N/A
- ZVSA N/A
- P/E Ratio
- ISPC N/A
- ZVSA N/A
- Revenue Growth
- ISPC N/A
- ZVSA N/A
- 52 Week Low
- ISPC $0.86
- ZVSA $0.47
- 52 Week High
- ISPC $11.80
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- ISPC 37.62
- ZVSA 53.43
- Support Level
- ISPC $0.86
- ZVSA $0.61
- Resistance Level
- ISPC $0.97
- ZVSA $0.73
- Average True Range (ATR)
- ISPC 0.06
- ZVSA 0.07
- MACD
- ISPC -0.02
- ZVSA 0.00
- Stochastic Oscillator
- ISPC 18.79
- ZVSA 36.53
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.